Sugi Predict

Sugi Predict / Compounds / SCHEMBL4148079

SCHEMBL4148079

SCHEMBL4148079

Cc1c(C=O)c2c3c(Cl)cc(=O)[nH]c3ccc2n1Cc1ccccc1

nearest known ligand 0.52

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 4/20 0.52
▸ ALDH1A1 P00352 2/20 0.52
▸ NPSR1 Q6W5P4 1/20 0.52
▸ AR P10275 1/20 0.47
▸ ERN1 O75460 1/20 0.41
▸ HPGD P15428 2/20 0.41
▸ CYP3A4 P08684 1/20 0.40
▸ KMT2A Q03164 2/20 0.40
▸ BRD4 O60885 1/20 0.40
▸ HSD17B10 Q99714 1/20 0.40
▸ PGR P06401 2/20 0.39
▸ MEN1 O00255 1/20 0.39
▸ VDR P11473 1/20 0.39
▸ PLA2G2A P14555 1/20 0.39
▸ ACHE P22303 1/20 0.38
▸ POLB P06746 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4145087 0.84 AR (0.47) LMNAALDH1A1NPSR1ARERN1
SCHEMBL4138453 0.72 AR (0.62) LMNAALDH1A1ARERN1HPGD
SCHEMBL14149362 0.72 LMNA (0.61) LMNAALDH1A1NPSR1PLA2G2A
SCHEMBL10624841 0.69 LMNA (0.79) LMNAALDH1A1NPSR1KMT2AMEN1
SCHEMBL4140291 0.69 AR (0.56) LMNAARERN1KMT2AHSD17B10
SCHEMBL4152899 0.68 AR (0.57) LMNAARERN1PGR
SCHEMBL4147947 0.68 AR (0.77) LMNAARPGR
SCHEMBL4151770 0.68 AR (0.54) ALDH1A1ARHPGDKMT2AMEN1
SCHEMBL4138548 0.68 AR (0.65) LMNAARPGR
SCHEMBL4144703 0.67 AR (0.53) LMNAARERN1PGR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8580811-B2 Androgen receptor modulator methods LIGAND PHARMACEUTICALS INCORPORATED (US) 2013-11-12 — — US claimed
US-20120165362-A1 Androgen receptor modulator compounds and methods LIGAND PHARMACEUTICALS INCORPORATED 2012-06-28 — — US claimed
US-8193357-B2 Androgen receptor modulator compounds LIGAND PHARMACEUTICALS INCORPORATED (US) 2012-06-05 — — US claimed
US-20090264455-A9 Androgen Receptor Modulator Compounds and Methods LIGAND PHARMACEUTICALS INCORPORATED (US) 2009-10-22 — — US claimed
US-20090030027-A1 Androgen Receptor Modulator Compounds and Methods LIGAND PHARMACEUTICALS INCORPORATED (US) 2009-01-29 — — US claimed
CN-101137655-A Androgen receptor modulator compounds and methods LIGAND PHARM INC (US) 2008-03-05 — — CN claimed
EP-1891067-B1 ANDROGEN RECEPTOR MODULATOR COMPOUNDS AND METHODS LIGAND PHARM INC (US) 2016-01-13 — — EP disclosed
EP-1891067-B1 ANDROGEN RECEPTOR MODULATOR COMPOUNDS AND METHODS LIGAND PHARM INC (US) 2016-01-13 — — EP disclosed
US-8580811-B2 Androgen receptor modulator methods LIGAND PHARMACEUTICALS INCORPORATED (US) 2013-11-12 — — US disclosed
US-8580811-B2 Androgen receptor modulator methods LIGAND PHARMACEUTICALS INCORPORATED (US) 2013-11-12 — — US disclosed
US-8580811-B2 Androgen receptor modulator methods LIGAND PHARMACEUTICALS INCORPORATED (US) 2013-11-12 — — US disclosed
US-20120165362-A1 Androgen receptor modulator compounds and methods LIGAND PHARMACEUTICALS INCORPORATED 2012-06-28 — — US disclosed
US-20120165362-A1 Androgen receptor modulator compounds and methods LIGAND PHARMACEUTICALS INCORPORATED 2012-06-28 — — US disclosed
US-20090264455-A9 Androgen Receptor Modulator Compounds and Methods LIGAND PHARMACEUTICALS INCORPORATED (US) 2009-10-22 — — US disclosed
US-20090264455-A9 Androgen Receptor Modulator Compounds and Methods LIGAND PHARMACEUTICALS INCORPORATED (US) 2009-10-22 — — US disclosed
US-20090264455-A9 Androgen Receptor Modulator Compounds and Methods LIGAND PHARMACEUTICALS INCORPORATED (US) 2009-10-22 — — US disclosed
US-20090030027-A1 Androgen Receptor Modulator Compounds and Methods LIGAND PHARMACEUTICALS INCORPORATED (US) 2009-01-29 — — US disclosed
US-20090030027-A1 Androgen Receptor Modulator Compounds and Methods LIGAND PHARMACEUTICALS INCORPORATED (US) 2009-01-29 — — US disclosed
US-20090030027-A1 Androgen Receptor Modulator Compounds and Methods LIGAND PHARMACEUTICALS INCORPORATED (US) 2009-01-29 — — US disclosed
CN-101137655-A Androgen receptor modulator compounds and methods LIGAND PHARM INC (US) 2008-03-05 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090030027-A1 Androgen Receptor Modulator Compounds and Methods AR, NR5A1, ESRRA LMNA 3994/4885ALDH1A1 1373/4885NPSR1 138/4885
US-20120165362-A1 Androgen receptor modulator compounds and methods AR, NR5A1, ESRRA LMNA 3994/4885ALDH1A1 1373/4885NPSR1 138/4885
US-20090264455-A9 Androgen Receptor Modulator Compounds and Methods AR, NR5A1, ESRRA LMNA 3994/4885ALDH1A1 1373/4885NPSR1 138/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.